Nature Communications (Apr 2019)
Defective homologous recombination DNA repair as therapeutic target in advanced chordoma
- Stefan Gröschel,
- Daniel Hübschmann,
- Francesco Raimondi,
- Peter Horak,
- Gregor Warsow,
- Martina Fröhlich,
- Barbara Klink,
- Laura Gieldon,
- Barbara Hutter,
- Kortine Kleinheinz,
- David Bonekamp,
- Oliver Marschal,
- Priya Chudasama,
- Jagoda Mika,
- Marie Groth,
- Sebastian Uhrig,
- Stephen Krämer,
- Christoph Heining,
- Christoph E. Heilig,
- Daniela Richter,
- Eva Reisinger,
- Katrin Pfütze,
- Roland Eils,
- Stephan Wolf,
- Christof von Kalle,
- Christian Brandts,
- Claudia Scholl,
- Wilko Weichert,
- Stephan Richter,
- Sebastian Bauer,
- Roland Penzel,
- Evelin Schröck,
- Albrecht Stenzinger,
- Richard F. Schlenk,
- Benedikt Brors,
- Robert B. Russell,
- Hanno Glimm,
- Matthias Schlesner,
- Stefan Fröhling
Affiliations
- Stefan Gröschel
- Molecular Leukemogenesis Group, German Cancer Research Center (DKFZ)
- Daniel Hübschmann
- Division of Theoretical Bioinformatics, DKFZ
- Francesco Raimondi
- BioQuant, Heidelberg University
- Peter Horak
- German Cancer Consortium (DKTK)
- Gregor Warsow
- Division of Theoretical Bioinformatics, DKFZ
- Martina Fröhlich
- German Cancer Consortium (DKTK)
- Barbara Klink
- Institute for Clinical Genetics, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden
- Laura Gieldon
- Institute for Clinical Genetics, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden
- Barbara Hutter
- German Cancer Consortium (DKTK)
- Kortine Kleinheinz
- Division of Theoretical Bioinformatics, DKFZ
- David Bonekamp
- Division of Radiology, DKFZ
- Oliver Marschal
- Onkologische Schwerpunktpraxis
- Priya Chudasama
- German Cancer Consortium (DKTK)
- Jagoda Mika
- Molecular Leukemogenesis Group, German Cancer Research Center (DKFZ)
- Marie Groth
- Division of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and DKFZ
- Sebastian Uhrig
- German Cancer Consortium (DKTK)
- Stephen Krämer
- Division of Theoretical Bioinformatics, DKFZ
- Christoph Heining
- DKTK
- Christoph E. Heilig
- Division of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and DKFZ
- Daniela Richter
- DKTK
- Eva Reisinger
- Division of Theoretical Bioinformatics, DKFZ
- Katrin Pfütze
- German Cancer Consortium (DKTK)
- Roland Eils
- German Cancer Consortium (DKTK)
- Stephan Wolf
- German Cancer Consortium (DKTK)
- Christof von Kalle
- German Cancer Consortium (DKTK)
- Christian Brandts
- University Cancer Center Frankfurt (UCT), Department of Medicine, Hematology/Oncology, Goethe University
- Claudia Scholl
- German Cancer Consortium (DKTK)
- Wilko Weichert
- Institute of Pathology, Technical University Munich
- Stephan Richter
- DKTK
- Sebastian Bauer
- West German Cancer Center, University of Duisburg-Essen
- Roland Penzel
- German Cancer Consortium (DKTK)
- Evelin Schröck
- Institute for Clinical Genetics, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden
- Albrecht Stenzinger
- German Cancer Consortium (DKTK)
- Richard F. Schlenk
- Department of Internal Medicine V, Heidelberg University Hospital
- Benedikt Brors
- German Cancer Consortium (DKTK)
- Robert B. Russell
- BioQuant, Heidelberg University
- Hanno Glimm
- DKTK
- Matthias Schlesner
- German Cancer Consortium (DKTK)
- Stefan Fröhling
- German Cancer Consortium (DKTK)
- DOI
- https://doi.org/10.1038/s41467-019-09633-9
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 9
Abstract
Chordomas are rare bone tumors with limited therapeutic options. Here, the authors identify molecular alterations associated with defective homologous recombination DNA repair in advanced chordomas and report prolonged response in a patient treated with a PARP inhibitor, which later acquired resistance due to a newly gained PARP1 mutation.
